Illegal Abortion Kits Racket Busted In Maharashtra, Case Against 8

Illegal Abortion Kits Racket Busted In Maharashtra, Case Against 8

---

Maharashtra FDA seizes 76 MTP kits across Nagpur and Solapur, books doctors, suppliers, and IndiaMART executives under the Drugs and Cosmetics Act and NDPS Act. New Delhi – August 14, 2026: The Maharashtra Food and Drug Administration (FDA) has dismantled a clandestine network involved in the illegal purchase and sale of medical abortion kits, registering criminal cases against eight individuals—including executives and directors of the online marketplace IndiaMART—following coordinated raids in Nagpur and Solapur districts on August 12, 2026. The operation, which resulted in the seizure of 76 MTP (Medical Termination of Pregnancy) kits alongside psychotropic and erectile dysfunction drugs valued at Rs 54,181, underscores a persistent regulatory failure in policing prescription-only abortion medication in India’s digital and physical supply chains. The action, confirmed by FDA Commissioner Tukaram Mundhe on Friday, comes amid a broader state-wide crackdown on unlicensed medicine sales that has already drawn e-commerce giants Amazon and Flipkart into the regulatory crosshairs. For Indian women, the raids expose a dangerous paradox: while medical abortion is legal and safer than ever under the amended MTP Act, the unsupervised distribution of these potent drugs continues to pose a significant threat to maternal health.

Coordinated Raids: Nagpur Clinic and Solapur Residence Under Scanner

The FDA’s Nagpur and Solapur offices executed the raids simultaneously on August 12, 2026, following intelligence regarding unauthorised storage and sale of abortion-inducing medicines. In Nagpur, a joint team of FDA officials and local police conducted a surprise inspection of Dr Sachin Marghade’s Shree Sai Clinic in Vinoba Bhave Nagar. The inspection yielded a substantial quantity of medicines stored for unauthorised sale, including Alprazolam and Sildenafil, collectively valued at Rs 45,649. The most incriminating evidence, however, was the condition of the abortion kits themselves. Officials found that labels and batch numbers on Prega End and Misopril kits—both used for medical termination of pregnancy—had been deliberately removed or obscured with black ink. This tampering, a clear violation of the Drugs and Cosmetics Act, 1940, is a hallmark of grey-market diversion, designed to prevent tracing of the supply chain back to manufacturers or wholesalers.

Police Trap Nets 50 Kits, Two Arrests in Nagpur

Beyond the clinic inspection, Nagpur police laid a strategic trap to capture the supply chain in action. The operation led to the arrest of two individuals allegedly involved in the distribution network. A search of the accused revealed they were carrying a total of 50 MTP kits—six kits in one person’s possession and 44 in the other’s—concealed in their bags. Police have registered a case against Dr Marghade and three others at the Yashodhara Nagar police station, invoking provisions of the Bharatiya Nyaya Sanhita (BNS) and the Narcotic Drugs and Psychotropic Substances Act (NDPS Act). The inclusion of the NDPS Act is notable, as it signals the authorities’ intent to treat the unauthorised trade in these substances with the severity reserved for controlled narcotics. Police are currently searching for the individual who allegedly supplied the kits to the arrested men.

Solapur Raid Exposes IndiaMART’s Role in Online Sales

In a parallel operation, the FDA and local police raided a residence in Solapur belonging to an individual suspected of selling abortion medicines directly to customers through the IndiaMART portal. The raid resulted in the seizure of 26 MTP kits valued at Rs 9,532. Critically, investigators determined that the stock had been sourced from outside Maharashtra, indicating a cross-state trafficking network. The probe revealed the online portal’s direct involvement in facilitating the sale, leading police to register a case against the directors of IndiaMART and three others at the MIDC police station in Solapur. This is not the first time IndiaMART has faced scrutiny. The platform, which hosts millions of sellers, has repeatedly been cited for listing prescription-only drugs. However, the direct naming of its directors in a criminal case marks a significant escalation in regulatory enforcement. The FDA’s action signals that online marketplaces can no longer claim the status of passive intermediaries when their platforms are used to peddle dangerous pharmaceuticals.

Legal Framework: A Triad of Statutes Underpins the Crackdown

The cases in both districts have been filed under a complex web of Indian law, reflecting the multi-faceted illegality of the operation. The primary charge falls under the Drugs and Cosmetics Act, 1940, which strictly prohibits the unauthorised storage, sale, and distribution of prescription-only medicines. MTP drugs, containing mifepristone and misoprostol, are classified as Schedule H drugs under this Act, meaning they can only be sold against a valid prescription from a registered medical practitioner. The Medical Termination of Pregnancy Act, 1971 (amended 2021), provides the legal framework for abortion in India, explicitly limiting the procedure to registered medical practitioners and specifying approved facilities. The sale of these kits without a prescription violates the very core of this legislation. The additional invocation of the NDPS Act in Nagpur, concerning the seizure of Alprazolam (a psychotropic substance), and the Bharatiya Nyaya Sanhita for criminal conspiracy, demonstrates the FDA’s determination to pursue the harshest possible penalties.

Health Risks: The Clinical Reality of Unsupervised Abortion

FDA Commissioner Tukaram Mundhe issued a stark warning alongside the announcement of the raids, emphasising that buying MTP kits or using them without a doctor’s prescription could lead to serious health complications. This warning is grounded in clinical reality. Medical abortion using a combination of mifepristone and misoprostol is a safe procedure when administered under medical supervision. However, unsupervised use can lead to severe haemorrhage, incomplete abortion, and life-threatening infections. In the Indian context, where unsafe abortion remains a significant contributor to maternal mortality, the availability of these kits on the black market is a public health hazard. Women who purchase these drugs online or from unlicensed vendors often do so without knowing the gestational age of their pregnancy, which is a critical determinant of the drugs’ safety and efficacy. The deliberate erasure of batch numbers, as seen in the Nagpur seizure, also means that counterfeit or substandard products cannot be recalled or traced, further endangering patients.

Broader Crackdown: Amazon, Flipkart, and the E-Commerce Frontier

The Nagpur and Solapur actions are part of a larger, aggressive enforcement drive by the Maharashtra FDA. In recent weeks, the FDA’s Drugs Department has conducted raids across Nagpur, Kolhapur, Thane, Akola, and Mumbai, targeting the illegal drug trade and unlicensed medicine sales. The regulatory authority has also sent formal notices to e-commerce behemoths Amazon and Flipkart over the alleged unauthorised selling of abortion kits and pills online. To substantiate these complaints, FDA officials have resorted to posing as customers and placing test orders to verify the illegal transactions. This proactive investigative technique indicates a shift from reactive policing to strategic enforcement. The notices to Amazon and Flipkart, coupled with the criminal case against IndiaMART’s directors, send a clear message: online platforms must implement robust verification mechanisms for sellers of pharmaceutical products or face legal consequences. The Drugs and Cosmetics Act, 1940, prohibits the online distribution of prescription medicines, a rule that has been repeatedly flouted by third-party sellers on these platforms.

The Bottom Line: A Systemic Failure and a Regulatory Reckoning

The busting of this racket is a significant victory for the Maharashtra FDA, but it also lays bare a systemic failure in India’s pharmaceutical distribution network. The seizure of 76 kits across two districts represents only a fraction of the illicit trade that likely flows through the state. The involvement of a medical professional in Nagpur is particularly troubling, as it suggests that the erosion of ethical boundaries is not limited to street-level peddlers but extends into the clinical setting. For Indian patients, particularly women in rural and semi-urban areas, the crackdown is a double-edged sword. While it restricts access to potentially dangerous, unregulated drugs, it also highlights the barriers to safe, legal abortion services. The FDA’s stringent action, while necessary, must be accompanied by efforts to improve access to certified providers and telemedicine services that comply with the MTP Act. The fight against illegal abortion kits is not just a law enforcement issue; it is a fundamental component of India’s maternal health strategy. The Maharashtra FDA has drawn a line in the sand, but the onus is now on the broader healthcare system to ensure that safe, legal pathways remain accessible to all women. — By Dr. Raj Patel, Staff Writer

This article was produced with AI-assisted research and editorial support. Reporting is based on sources cited in the article.